12th Annual European Congress: Preliminary Program

Program - Monday, 26 October 2009
07:00 – 08:00
EDUCATIONAL SYMPOSIUM - Sponsored by UBC and Shire
Comparative Effectiveness: Can the Agencies’ Demands Be Met?
08:00 – 08:30
EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
08:30 – 09:45
SECOND PLENARY SESSION
Performance-based Agreements - Theory to Practice
Health care performance-based agreements are agreements between a party who agrees to provide a health care product (drug or medical device) or a service (doctors to patients) to another party (the payer of the product or service) in which there are uncertainties of its real value. The provider has sufficient confidence in the value of the product or service and is ready to accept a reward or penalty depending on the observed performance of the product or service in the real world. Both the provider and the payer support the financial consequence of reducing uncertainty. Such an agreement includes the design and the cost of the observational procedure to assess the performance of the product or service in real life. During this session, performance-based agreements, the prerequisites for implementing a performance-based agreement, and what are the pros and cons of these agreements for both the payer and the provider of the product or service will be presented and debated.

8:30 – 8:35 Gérard de Pouvourville PhD Moderator: Gérard de Pouvourville PhD, Professor and Chair of Health Economics, ESSEC Business School, Cergy-Pontoise, France
8:35 – 8:55 Sean D. Sullivan PhD, RPh Speaker: Sean D. Sullivan PhD, RPh, Professor of Pharmacy and Public Health and Director, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
8:55 – 9:15 Jens Grueger PhD Speaker: Jens Grueger PhD, Vice President, Head Global Market Access Primary Care, Pfizer Ltd, Tadsworth, Surrey, UK
9:15 – 9:30 M. Noël Renaudin PhD Speaker: M. Noël Renaudin, Chairman, Comité Economique des Produits de Santé, Ministry of Health, Youth and Sports, Paris, France
9:30 – 9:45   DISCUSSION
09:45 – 10:15
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
10:15 – 11:15
RESEARCH PODIUM PRESENTATIONS – SESSION I (5 Concurrent)
10:15 – 11:15
ADHERENCE/COMPLIANCE STUDIES
AC1 PERSISTENCE WITH ANTIHYPERTENSIVE DRUG CLASSES; INFLUENCE OF METHOD ASSUMPTIONS
  Nguyen NH, Vegter S, Visser ST, Postma MJ, de Jong-van den Berg LTW, Boersma C
  University of Groningen, Groningen, The Netherlands
AC2 SUCCESS FACTORS IMPROVING PATIENT COMPLIANCE BEHAVIOUR - EMPIRICAL FINDINGS FROM EUROPE
  Schäfer C
  Johannes Gutenberg-University of Mainz, Mainz, Germany
AC3 NON-ADHERENCE IN OUTPATIENT THROMBOSIS PROPHYLAXIS AFTER MAJOR ORTHOPAEDIC SURGERY
  Wilke T
  University of Wismar, Wismar, Germany
AC4 A RETROSPECTIVE COHORT STUDY OF MEDICATION ADHERENCE TO TREATMENT OF OSTEOPOROSIS IN A SWEDISH POPULATION
  Landfeldt E1, Borgström F1, Robbins S2, Ström O1
  1i3 Innovus, Stockholm, Sweden, 2Amgen Europe GmbH, Zug, Switzerland
10:15 – 11:15
CANCER STUDIES I
CN1 HOW MUCH DOES ADJUSTING FOR HEALTH-RELATED QUALITY OF LIFE MATTER IN COST-EFFECTIVENESS ANALYSIS? A COMPARISON OF COST/LIFE YEAR AND COST/QALY ESTIMATES FOR CANCER INTERVENTIONS
  Greenberg D, Cohen JT, Fang C, Neumann PJ
  Tufts Medical Center, Boston, MA, USA
CN2 ECONOMIC EVALUATION OF THE CHEK2 GENOTYPING AND PERSONALIZED BREAST CANCER SCREENING IN THE POLISH HEALTH CARE SYSTEM
  Orlewska E1, Lubinski J2
  1Centrum Farmakoekonomiki, Warsaw, Poland, 2Pomeranian Medical University, Szczecin, Poland
CN3 COST-EFFECTIVENESS OF SORAFENIB IN UNRESECTABLE AND/OR METASTATIC RENAL CELL CARCINOMA IN TURKEY
  Tatar M1, Akbulut H2
  1Hacettepe University, Ankara, Turkey, 2Ankara University Medical School, Ankara, Turkey
CN4 COST-EFFECTIVENESS OF PEMETREXED IN FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PORTUGAL
  Pinto CG1, Manaças M2, Miguel LS3
  1Technical University of Lisbon, Lisboa, Portugal, 2Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal, 3Research Centre on the Portuguese Economy - CISEP, Lisboa, Portugal
10:15 – 11:15
IMPACT OF DRUG EXPENDITURE CONTROL
DE1 MARKET CONCENTRATION AND ITS CROSS-LINKAGE WITH THE CONSUMPTION OF ACE INHIBITORS AND ARBS
  Zhang JX1, Tao J2
1Virginia Commonwealth University, Richmond, VA, USA, 2Virginia Commonwealth University, Richmond , VA, USA
DE2 INFLUENCE OF GENERIC DRUGS ON PROTON PUMP INHIBITOR PRESCRIPTION IN PRIMARY CARE
  Cammarota S1, De Portu S2, Citarella A1, Menditto E1, Cuomo R1
  1University of Naples, Naples, Italy, 2University Federico II, Naples, Italy
DE3 HAVE RECENT PHARMACEUTICAL REFORMS DAMAGED R&D?
  Trushin EF
  Queen Mary University of London, London, UK
DE4 PRESCRIPTION DRUG FORMULARIES AND COVERAGE: DOES A DRUG BY ANY OTHER NAME SMELL AS SWEET?
  Hsu J, Price M, Fung V
  Kaiser Permanente, Oakland, CA, USA
10:15 – 11:15
MENTAL HEALTH - MODELING STUDIES
MH1 A DISCRETE EVENT SIMULATION MODEL IN MAJOR DEPRESSIVE DISORDER – COST-EFFECTIVENESS ANALYSIS OF AGOMELATINE
  Félix J1, Almeida J1, Varandas P2
  1Exigo Consultores, Alhos Vedros, Lisbon, Portugal, 2Hospital dos Lusíadas, Lisbon, Portugal
MH2 THE COST-EFFECTIVENESS OF OPPORTUNISTIC SCREENING AND MINIMAL CONTACT PSYCHOTHERAPY TO PREVENT DEPRESSION IN PRIMARY CARE PATIENTS
  Van den Berg M1, Smit F2, Vos T3, Van Baal P4
  1National Institute for Public Health and the Environment, Bilthoven, The Netherlands, 2Trimbos Institute (The Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands, 3University of Queensland, Brisbane, Australia, 4National Institute for Public Health and the Enviroment, Bilthoven, The Netherlands
MH3 ANTIPSYCHOTIC USE AND DIABETES: A NESTED CASE-CONTROL ANALYSIS IN A COHORT OF NEW ANTIPSYCHOTIC USERS
  Moisan J1, Desjardins O2, Turgeon M3, Grégoire JP1
  1Université Laval, Québec, QC, Canada, 2Bristol-Myers Squibb Canada, St-Laurent, QC, Canada, 3Faculté de pharmacie, Université Laval, Québec, QC, Canada
MH4 COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 DIABETES MELLITUS (T2DM): EFFECTS ON QUALITY OF LIFE AND RESOURCE USE
  Purayidathil FW, Gupta S, Wagner S
  Consumer Health Sciences International (a KantarHealth Company), Princeton, NJ, USA
10:15 – 11:15
UTILITY MEASUREMENTS STUDIES
UT1 VALUING EQ-5D USING TIME TRADE-OFF IN FRANCE
  Chevalier J1, De Pouvourville G2
  1Institut Gustave Roussy, Villejuif Cedex, France, 2ESSEC Business School, Cergy Pontoise Cedex, France
UT2 PARADIGM LOST: A CONCEPTUAL AND EMPIRICAL OBITUARY CHRONICLING THE DEMISE OF CARDINAL UTILITY MEASUREMENTNT
  Kind P
  University of York, York, UK
UT3 HEALTHY-DAYS TIME EQUIVALENTS FOR OUTCOMES OF ACUTE ROTAVIRUS INFECTIONS
  Hauber AB1, Johnson FR1, Cook JR2, Mohamed AF1, Gonzalez JM1, Walter E3
  1RTI Health Solutions, Research Triangle Park, NC, USA, 2Merck and Co. Inc, North Wales, PA, USA, 3Duke University, Durham, NC, USA
UT4 DEVELOPING AND PRELIMINARY TESTING OF AN OFFICIAL FIVE-LEVEL VERSION OF EQ-5D
  Herdman M1, Gudex C2, Lloyd A3, Janssen B4, Kind P5, Parkin D6, Bonsel GJ7, Badia X8
  1Insight Consulting & Research, Mataró, Barcelona, Spain, 2Odense University Hospital, Odense, Denmark, 3Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, 4EuroQol Group Executive Office, Rotterdam, The Netherlands, 5University of York, York, UK, 6City University, London, UK, 7Erasmus Medical Centre, Rotterdam, n/a, The Netherlands, 8IMS Health, Barcelona, Spain
11:30 – 12:30
ISSUE PANELS – SESSION I (5 Concurrent)
11:30 – 12:30 IP1: THE UK NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE): NEW DEVELOPMENTS
Moderator: Stephen Beard MSc, Head of Health Economics, RTI Health Solutions, Manchester, UK
Panelists: Carole Longson PhD, Director, Centre for Health Technology Evaluation, NICE, Manchester, UK; Matt D Stevenson PhD, Technical Director, School of Health and Related Research Technology Assessment Group (ScHARR-TAG), University of Sheffield, Sheffield, UK; Sorrel E Wolowacz PhD, Senior Health Economist, RTI Health Solutions, Manchester, UK
11:30 – 12:30 IP2: PHARMACEUTICAL POLICIES IN EUROPEAN COUNTRIES: AIMING AT COST CONTAINMENT, COST-EFFECTIVENESS, OR EQUITY?
Moderator: Ivar Sønbø Kristiansen MD, PhD, MPH, Professor, Institute of Health Management and Health Economics, University of Oslo, Oslo, Norway
Panelists: John Hutton PhD, Professor of Health Economics, Department of Health Sciences - Health Economics, University of York, York, UK; Marc Koopmanschap PhD, Researcher, Institute for Medical Technology Assessment, Erasmus MC, Rotterdam, The Netherlands; Ewa Orlewska MD, PhD, Lecturer, Centrum Farmakoekonomiki, Warsaw, Poland
11:30 – 12:30 IP3: THE DEVIL IS IN THE DETAILS: INTERNATIONAL COMPARISON OF TECHNOLOGY ASSESSMENT PROCESSES AND PAYER UPTAKE OF PERSONALIZED MEDICINE AND IMPLICATIONS FOR THE FIELD
Moderator: Eric C Faulkner MPH, Senior Director, Pricing & Reimbursement, RTI Health Solutions, Research Triangle Park, NC, USA
Panelists: Lieven Annemans PhD, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Uwe Siebert MD, MPH, MSc, Professor, UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i.T, Austria; Katherine Payne PhD, Senior Research Fellow, University of Manchester, Manchester, UK
11:30 – 12:30 IP4: WHAT SHOULD BE THE ROLE OF PATIENT PREFERENCES IN MAKING HEALTHCARE RESOURCE ALLOCATION DECISIONS?
Moderator: Michael F Drummond DPhil, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
Panelists: John FP Bridges PhD, Assistant Professor, Bloomberg School of Public Health, Health Policy and Management, Johns Hopkins University, Baltimore, MD, USA; Deborah A Marshall PhD, Associate Professor, Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada; Mark J Sculpher PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
11:30 – 12:30 IP5: PATIENT-REPORTED OUTCOMES AS A STANDARD APPROACH FOR HEALTH CARE POLICY MAKERS
Moderator: Andrew Bottomley PhD, Assistant Director, Head Quality of Life Department, EORTC, Brussels, Belgium
Panelists: Chantal Quinten MSc, Researcher, Quality of Life Department, EORTC, Brussels, Belgium; Carolyn Gotay PhD, Professor, University of British Columbia, Vancouver, BC, Canada
12:30 – 14:00
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
 
12:45 – 13:45
EDUCATIONAL SYMPOSIUM - Sponsored by IMS
New Developments in Health Technology Assessment (HTA): How Does This Impact Health Economics and Outcomes Research?
14:00 – 15:00
RESEARCH PODIUM PRESENTATIONS – SESSION II (5 Concurrent)
14:00– 15:00
CANCER STUDIES II
CN5 COSTS OFT QALYS GAINED IN A PALLIATIVE CARE UNIT (PCU) IN GERMANY
  Schuler US1, Schubert BT2, Haag C1
  1University of Dresden, Dresden, Saxony, Germany, 2St .Joseph Stift Hospital, Dresden, Saxony, Germany
CN6 TREATMENT-RELATED TOXICITIES IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
  Yood MU1, Wang F(2, Zhao Z2, Alford SH3, Oliveria S1, Wells K3, Phillips S4, Ali H3, O'Malley C5, Barber B6
  1Epi Source, hamden, CT, USA, 2Amgen Inc, Thousand Oaks, CA, USA, 3Henry Ford Health System, Detroit, MI, USA, 4Epi Source, Hamden, CT, USA, 5Amgen, Inc, Thousand Oaks, CA, USA, 6Amgen Inc., Thousand Oaks, CA, USA
CN7 TREATMENT VARIATION COMPLICATES REAL-WORLD PHARMACOECONOMICS: DAILY CLINICAL PRACTICE OF BORTEZOMIB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
  Franken M1, Gaultney J1, Huijgens P2, Redekop W1, Uyl-de Groot C1
  1Erasmus University Medical Center, Rotterdam, The Netherlands, 2VU University Medical Center, Amsterdam, The Netherlands
CN8 METHODOLOGICAL ISSUES OF CONTROL ARM ADJUSTMENTS FOR COMPARATIVE EFFECTIVENESS ASSESSMENTS: AN EXAMPLE BASED ON THE COMPARISON OF FIRST-LINE BEVACIZUMAB + INTERFERON ALPHA-2A VS SUNITINIB IN RENAL CELL CARCINOMA
  Schwander B1, Mickisch GH2, Walzer S3, Siebert U4
  1AiM GmbH Assessment in Medicine, Schopfheim, Germany, 2Center of Operative Urology Bremen, Bremen, Germany, 3F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland, 4UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i.T, Austria
14:00– 15:00
ECONOMIC EVALUATION AND REIMBURSEMENT DECISIONS I
EE1 USING IQWIG'S EFFICIENCY FRONTIER APPROACH FOR THE ECONOMIC EVALUATION OF HEAPTITIS C TREATMENT – A PILOT AND FEASIBILITY STUDY COMMISSIONED BY IQWIG
  Siebert U, Mühlberger N, Conrads-Frank A, Sroczynski G, Schwarzer R
  UMIT - University for Health Sciences, Hall, Austria
EE2 DEAR POLICYMAKER: HAVE YOU MADE UP YOUR MIND?
  Koopmanschap M1, Stolk E2, Koolman XH3
  1Erasmus MC, Rotterdam, The Netherlands, 2Erasmus Medical Center, Rotterdam, The Netherlands, 3Delft University of Technology, Delft, The Netherlands
EE3 IS NICE TOO NASTY? A COMPARISON OF ANTICANCER DRUG COVERAGE DECISIONS IN THE UNITED STATES AND UK
  Mason AR1, Drummond MF1, Ramsey SD2, Campbell JD3, Raisch DW4
  1University of York, York, N. Yorkshire, UK, 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA, 4University of New Mexico College of Pharmacy, Albuquerque, NM, USA
EE4 MARKET ACCESS IN GERMANY: WHERE NEXT?
  Zoellner YF1, Schaefer M2
  1Mapi Values, Houten, The Netherlands, 2Charité University Medicine, Berlin, Germany
14:00– 15:00
MODELING METHODS I
MO1 COHORT MODELLING - IS THE APPROACH TOO OLD FOR THE ELDERLY?
  Ethgen O1, Demarteau N2, Standaert BA2
  1University of Liège, Liège, Belgium, 2GlaxoSmithKline Biologicals, Rixensart, Belgium
MO2 IMPROVING COST-EFFECTIVENESS ANALYSES OF BEHAVIOURAL INTERVENTIONS BY USING COGNITIVE INTERMEDIATE OUTCOMES: A PILOT STUDY
  Prenger R1, Pieterse ME1, Braakman-Jansen LM1, van der Palen J2, Seydel ER1
  1University of Twente, Enschede, The Netherlands, 2Medisch Spectrum Twente Hospital, Enschede, The Netherlands
MO3 R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R.
  Bischof M, Lim ME, Ferrusi IL, Burke N, Blackhouse G, Goeree R, Tarride JE
  McMaster University, Hamilton, ON, Canada
MO4 BAYESIAN GENERALIZED LINEAR MODELLING OF THE RELATIONSHIP BETWEEN HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX AND HEALTH UTILITIES INDEX MARK III IN EARLY AND LATE RHEUMATOID ARTHRITIS: DATA FROM THE PREMIER AND ARMADA TRIALS
  Vanness D1, Roy S2, Benedict A3, Cifaldi M2
  1United BioSource Corporation, Madison, WI, USA, 2Abbott Laboratories, Abbott Park, IL, USA, 3United BioSource Corporation, London, UK
14:00– 15:00
PATIENT PREFERENCE STUDIES

PP1

A SYSTEMATIC REVIEW OF THE ANALYTIC HIERARCHY PROCESS IN HEALTH CARE DECISION MAKING

 

Hummel JM, IJzerman MJ

 

University of Twente, Enschede, The Netherlands

PP2

PATIENT PREFERENCES FOR BENEFIT-RISK TRADEOFFS AMONG POST-TRANSPLANT OUTCOMES IN END-STAGE RENAL DISEASE

 

Johnson FR1, Hauber AB1, Mohamed AF1, Gonzalez JM2

 

1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI HEalth Solutions, Research Triangle Park, NC, USA

PP3

WHAT DIMENSIONS ARE IMPORTANT TO PATIENTS IN THEIR EXPERIENCE OF CONTINUITY OF CARE? A STUDY OF PATIENTS' PREFERENCES USING A DISCRETE CHOICE EXPERIMENT

 

Kjaer T1, Bech M1, Draborg E1, Mollerup M2

 

1University of Southern Denmark, Odense, Denmark, 2Odense University Hospital, Odense, Denmark

PP4

LIVES WORTH LIVING: OLDER SMOKERS' STATED PREFERENCES FOR LONGEVITY

 

Johnson FR1, Smith VK2, Smith GA3, Gonzalez JM4

 

1RTI International, Research Triangle Park, NC, USA, 2Arizona State University, Tempe, AZ, USA, 3University of Michigan, Ann Arbor, MI, USA, 4RTI Health Solutions, Research Triangle Park, NC, USA

14:00– 15:00
VACCINES - COST EFFECTIVENESS ANALYSIS STUDIES

VA1

SEVEN, TEN OR THIRTEEN? THE COST-UTILITY OF INFANT VACCINATION WITH A 7-, 10- OR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN THE NETHERLANDS

 

Vemer P1, de Greeff SC2, Schouls LM2, Al MJ1, de Melker H2

 

1Erasmus MC, Rotterdam, The Netherlands, 2National Institute for Public Health and Environment (RIVM), Bilthoven, The Netherlands

VA2

A HEALTH ECONOMIC EVALUATION OF A NEW HERPES ZOSTER (HZ) VACCINE FOR THE PREVENTION OF HZ AND POST-HERPETIC NEURALGIA (PHN) IN BELGIUM

 

Annemans L1, Papageorgiou M2, Martin M3, Bresse X4

 

1Ghent University, Ghent, Belgium, 2i3 Innovus, Athens, Greece, 3i3 Innovus, Uxbridge, Middlesex, UK, 4Sanofi Pasteur MSD, Lyon, France

VA3

GLOBAL MEASLES ERADICATION: COST-EFFECTIVENESS AND IMPLICATIONS FOR GHANA, 2020-2049

 

Garrison L1, Bauch CT2, Babigumira JB1

 

1University of Washington, Seattle, WA, USA, 2University of Guelph, Guelph, ON, Canada

VA4

HEALTH ECONOMIC EVALUATION OF A NOVEL INTRADERMAL INFLUENZA VACCINE IN TWO EUROPEAN COUNTRIES

 

Reygrobellet C1, Hudeckova H2, Kristufkova Z3, Kyncl J4

 

1Sanofi pasteur, Lyon, France, 2Jessenius Medical Faculty Comenius University, Bratislava, Slovakia, Slovak Republic, 3Faculty of Public Health, Slovak Medical University, Bratislava, Slovak Republic, 4National Institute of Public Health , Praha, Praha 10, Czech Republic
15:00 – 15:15
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
15:15 – 16:15
RESEARCH PODIUM PRESENTATIONS – SESSION III (5 Concurrent)
15:15 - 16:15
HEALTH CARE DECISION-MAKER'S CASE STUDIES

CASE1

DESIGNING AND IMPLEMENTING OUTCOME-BASED REIMBURSEMENT SCHEMES: EXPERIENCE FROM HUNGARY

 

Dankó D, Molnár MP, Berta G

 

National Health Insurance Fund Administration (OEP), Budapest, Hungary

CASE2

 REVIEW OF THE EARLY EXPERIENCE OF THE NEW NICE SCIENTIFIC ADVICE PROGRAMME

 

Phillips S, Doss S, Longson C

 

NICE, Manchester, UK

CASE3

THE SLOVAK EXPERIENCE IN THE INTERNATIONAL PRICE BENCHMARKING FOR PRESCRIPTION DRUGS

 

Filko M1, Szilagyiova P2

 

1Ministry of Finance of the Slovak Republic, Bratislava, Slovak Republic, 2Pfizer Slovakia, Bratislava, Slovak Republic

CASE4

ASSESSMENT AND APPRAISAL IN THE NETHERLANDS

 

Delwel GO1, Goettsch WG1, Cucic C2, Steenland E2, Terhell L2, Vingerhoed-van Aken BE2

 

1CVZ Healthcare Insurance Board, Diemen, The Netherlands, 2Netherlands Organisation for Health Research and Development (ZonMw), The Hague, The Netherlands

15:15 - 16:15
ECONOMIC EVALUATION AND REIMBURSEMENT DECISIONS II

EE5

THE SEESAW OF COST-EFFECTIVENESS THRESHOLDS: HOW RELAXED REQUIREMENTS FOR LATER LINES OF TREATMENT WILL INCREASE HURDLES FOR NEW THERAPIES

 

Liwing J, Lothgren M

 

Janssen-Cilag AB, Sollentuna, Sweden

EE6

INCORPORATING EQUITY IN COST-EFFECTIVENESS ANALYSIS: A SYSTEMATIC REVIEW

 

Johri M1, Norheim OF2

 

1Université de Montréal, Montreal, QC, Canada, 2University of Bergen, Bergen, Norway

EE7

A DISCRETE CHOICE EXPERIMENT COMPARING PUBLIC AND DECISION-MAKER STATED PREFERENCES FOR PHARMACEUTICAL SUBSIDY DECISIONS

 

Whitty JA, Scuffham PA, Rundle-Thiele SR

 

Griffith University, Brisbane, Queensland, Australia

EE8

BRIDGING HEALTH TECHNOLOGY ASSESSMENT WITH MULTICRITERIA DECISION ANALYSIS (MCDA) AND AN ETHICAL FRAMEWORK FOR COMPLEX DECISIONS: CASE STUDY OF GROWTH HORMONE FOR TURNER SYNDROME

 

Goetghebeur MM1, Wagner M1, Khoury H1, Rindress D1, Grégoire JP2, Deal C3

 

1BioMedCom Consultants Inc, Montreal, QC, Canada, 2Université Laval, Québec, QC, Canada, 3CHU Ste-Justine & University of Montréal, Montreal, QC, Canada

15:15 - 16:15
MODELING METHODS II

MO5

THE USE OF SURVIVAL ANALYSES FOR COST-EFFECTIVENESS MODELS: AN EVALUATION OF METHODS USED IN NICE APPRAISALS

 

Guyot P1, Ouwens M2

 

1Mapi Values Netherlands BV, Houten, The Netherlands, 2Mapi Values Netherlands B.V., Houten, The Netherlands

MO6

MODELLING COST EFFECTIVENESS OF DRUGS THAT DELAY DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS: A NOVEL APPROACH

 

Skedgel C1, Brown MG2, Andreou P1, Kirby S2

 

1Dalhousie University, Halifax, NS, Canada, 2Capital Health Nova Scotia, Halifax, NS, Canada

MO7

EVALUATION OF A BAYESIAN COMPREHENSIVE DECISION-ANALYTICAL MODELLING FRAMEWORK IN CHRONIC HEPATITIS C

 

Cawston H1, Aballéa S2, Cure S1

 

1i3 Innovus, Uxbridge, UK, 2i3 Innovus, Nanterre, France

MO8

MARGINAL STRUCTURAL MODELS FOR COMPARING THE EFFECTIVENESS OF MULTIPLE TREATMENTS IN OBSERVATIONAL STUDIES

 

Desai R, Johnson M

 

University of Houston, Houston, TX, USA

15:15 - 16:15
PRO/QOL METHODS - CROSS CULTURAL ADAPTATION

PR1

A LATENT GENERAL GROWTH MIXTURE MODEL FOR HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSON DISEASE ACROSS 36 MONTH

 

Reese JP1, Klotsche J2, Winter Y1, Wittchen HU2, Dodel R1

 

1Philipps-University, Marburg, Germany, 2Technische Universität Dresden, Dresden, Germany

PR2

DEVELOPMENT AND PSYCHOMETRIC PROPERTIES OF A PEDIATRIC PERCEIVED COGNITIVE FUNCTION ITEM BANK (PEDSPCF)

 

Lai JS1, Zelko F2, Butt Z1, Cella D1, Magasi S1, Goldman S2

 

1Northwestern University, Chicago, IL, USA, 2Children's Memorial Hospital, Chicago, Chicago, IL, USA

PR3

FIBROMYALGIA FATIGUE – DEVELOPMENT OF A CONCEPTUAL MODEL BASED ON QUALITATIVE PATIENT INTERVIEWS

 

Mease P1, Humphrey L2, Arbuckle R2, Williams DA3, Danneskiold-Samsoe B4, Gilbert C5

 

1Seattle Rheumatology Associates, Seattle, WA, USA, 2Mapi Values Ltd, Bollington, UK, 3University of Michigan, Ann Arbor, MI, USA, 4Frederiksberg Hospital, Frederiksberg, Denmark, 5Pfizer Ltd, Sandwich, UK

PR4

LINEAR SCORING RULES FOR PATIENT REPORTED OUTCOMES AND PATIENT PREFERENCES

 

Mohamed AF1, Hauber AB1, Johnson FR2

 

1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI International, Research Triangle Park, NC, USA

15:15 - 16:15
VACCINES - MODELING STUDIES

VA5

INDIVIDUALLY-BASED DYNAMIC MODELING OF INFECTIOUS DISEASES: COST-EFFECTIVENESS OF ADOLESCENT PERTUSSIS BOOSTER VACCINATION FOR THE NETHERLANDS

 

de Vries R, Postma M

 

University of Groningen, Groningen, The Netherlands

VA6

INTEGRATED DYNAMIC TRANSMISSION/COST-EFFECTIVENESS MODEL FOR INFLUENZA A AND B PART I: DEVELOPMENT OF AN INTEGRATED MODEL

 

Pitman RJ1, Leeuwenkamp O2

 

1Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, 2MedImmune, Cambridge, Cambridgeshire, UK

VA7

COMPARISON OF DIFFERENT STATIC AND DYNAMIC SIMULATION TECHNIQUES FOR THE INFLUENCE OF CHILDREN PNEUMOCOCCAL VACCINATION

 

Endel G1, Schiller - Frühwirth I1, Popper N2, Zauner G2, Breitenecker F3

 

1Hauptverband der Österreichischen Sozialversicherungsträger, Vienna, Vienna, Austria, 2DWH - Simulation Services, Vienna, Vienna, Austria, 3Vienna University of Technology, Vienna, Vienna, Austria

VA8

HOW SHOULD HEALTH GAINS OF VACCINATION STRATEGIES BE DISCOUNTED?

 

Westra TA1, Rogoza R2, Daemen T1, Wilschut JC1, Postma MJ3

 

1University Medical Center Groningen, Groningen, The Netherlands, 2i3 Innovus, Burlington, ON, Canada, 3University of Groningen, Groningen, The Netherlands

16:15 – 16:30
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION II
16:30 – 17:30
RESEARCH PODIUM PRESENTATIONS – SESSION IV (5 Concurrent)
16:30 - 17:30
COST STUDIES

CO1

ESTIMATE AVERAGE MEDICAL COSTS IN THE PRESENCE OF RIGHT-CENSORING

 

Guan S1, Peeters P2, Pedotti P1, Van Engen AK1

 

1Quintiles Consulting, Hoofddorp, The Netherlands, 2Quintiles Consulting, Levallois-Perret, France

CO2

WITHDRAWN

 

 

CO3

INDIRECT SOCIAL COST OF MULTIPLE SCLEROSIS: RESULTS FROM A REAL-WORLD OBSERVATIONAL STUDY

 

Kirzinger S1, Halper J2, Jeffery D3, Preblick R4, Bi YJ4, Bharmal M5, Jo H5

 

1University of Louisville, Louisville, KY, USA, 2MS Center at HNH, Teaneck, NJ, USA, 3Wake Forest University School of Medicine, Winston-Salem, NC, USA, 4Bayer HealthCare Pharmaceuticals, Inc., Health Economics, Outcome and Reimbursement (HEOR), Wayne, NJ, USA, 5Quintiles, Inc., Falls Church, VA, USA

CO4

MICRO-COSTING VS GROSS-COSTING IN THE ESTIMATION OF COSTS FOR THE PHARMACOECONOMIC EVALUATION OF GLAUCOMA IN KOREA

 

Kang SH, Lee EK

 

SookMyung Women's University, Seoul, South Korea

16:30 - 17:30
DIABETES STUDIES

DB1

USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES

 

Goeree R, Lim ME, Hopkins R, Blackhouse G, Tarride JE, Xie F, O'Reilly D

 

McMaster University, Hamilton, ON, Canada

DB2

PERSISTENCE WITH BASAL SUPPORTED ORAL THERAPY - COMPARISON OF INSULIN GLARGINE VERSUS NPH INSULIN

 

Quinzler R1, Ude M2, Franzmann A1, Feldt S1, Leuner K2, Mueller WE2, Dippel FW3, Schulz M4

 

1GIDE - German Institute for Drug Use Evaluation (DAPI), Eschborn, Hessen, Germany, 2Goethe-University, Frankfurt am Main, Hessen, Germany, 3Sanofi-Aventis, Berlin, Berlin, Germany, 4ABDA - Federal Union of German Associations of Pharmacists, Berlin, Berlin, Germany

DB3

USING ELECTRONIC MEDICAL RECORDS TO IDENTIFY UNDIAGNOSED DIABETES MELLITUS IN PRIMARY CARE PRACTICES

 

Marelli C1, Cload P2, Ross S3, Kallenbach L4, Haas S5, Gunnarsson C6, Zyczynski T7

 

1GE HealthCare LTD, Bucks, Giles Bucks, England, 2GE HealthCare LTD, Bucks, Bucks, England, 3SDRoss Consulting, Cohasset, MA, USA, 4GE Healthcare Clinical Data Services, Plano, TX, USA, 5s2 Statistical Solutions, Inc., Cincinnati, OH, USA, 6S2 Statistical Solutions, Inc, Cincinnati, OH, USA, 7GE Healthcare, Princeton, NJ, USA

DB4

RISK OF STROKE OR MYOCARDIAL INFARCTION OF T2DM PATIENTS TREATED WITH PIOGLITAZONE OR NON-THIAZOLIDINEDIONE IN A MANAGED CARE SETTING IN THE UNITED STATES

 

Sun SX1, Vallarino C2, Xu Y1, Kupfer S2, Bron M1

 

1Takeda Pharmaceuticals International, Inc, Deerfield, IL, USA, 2Takeda Global Research and Development Center, Inc, Deerfield, IL, USA

16:30 - 17:30
MODELING METHODS - HANDLING UNCERTAINTY

MO9

HANDLING UNCERTAINTY IN THE CASE OF COMBINED END-POINTS

 

Heeg BMS1, Treur MJ2, van Hout BA3

 

1Pharmerit Europe, Rotterdam, The Netherlands, 2PharMerit Europe, Rotterdam, Zuid-Holland, The Netherlands, 3Pharmerit Ltd, York, North Yorkshire, UK

MO10

EARLY MODELLING: METHODS IN THE ECONOMIC ANALYSIS OF PRE-PHASE II PRODUCTS

 

Taylor M, Saxby R

 

University of York, York, UK

MO11

WHEN DOES VALUE OF INFORMATION ANALYSIS ADD VALUE?

 

Ishak KJ1, Getsios D2, Caro JJ2

 

1United BioSource Corporation, Montreal, QC, Canada, 2United BioSource Corporation, Lexington, MA, USA

MO12

COMPARISON OF THREE META-MODELS FOR UNCERTAINTY ANALYSIS

 

Lieuw On MML1, Heeg BMS2, De Charro F2, van Hout BA3

 

1Pharmerit, Rotterdam, Zuid-Holland, The Netherlands, 2Pharmerit Europe, Rotterdam, The Netherlands, 3Pharmerit Ltd, York, North Yorkshire, UK

16:30 - 17:30
PRO/QOL METHODS - DEVELOPMENT

PR5

TRANSLATION AND LINGUISTIC VALIDATION: EVIDENCE TO SUGGEST THAT AN IN-COUNTRY REVIEW IS NECESSARY

 

Gergovich KB, Houchin C, Wild D

 

Oxford Outcomes Ltd, Oxford, UK

PR6

PRESENTATION OF THE ACTIVITIES OF THE ISOQOL TRANSLATION AND CULTURAL ADAPTATION SPECIAL INTEREST GROUP (TCA-SIG)

 

Conway K1, Patrick DL2, Martin M3, Eremenco S4, Petkova I1

 

1MAPI Research Trust, Lyon, France, 2University of Washington, Seattle, WA, USA, 3Health Research Associates, Inc., Seattle, WA, USA, 4Evanston Northwestern Healthcare Research Institute, Evanston, IL, USA

PR7

EVALUATION OF ALTERNATIVE METHODS OF TRANSLATING PATIENT-REPORTED OUTCOME MEASURES

 

McKenna SP1, Hagell P2, Hedin PJ3, Nyberg L2

 

1Galen Research, Manchester, UK, 2Lund University, Lund, Sweden, 3Central Hospital, FALUN, Sweden

PR8

VALIDATION OF THE PROQOL-HIV QUESTIONNAIRE IN LIGHT OF CROSS-CUTURAL DIFFERENCES FROM 5 CONTINENTS

 

Duracinsky M1, Acquadro C2, Lalanne C2, Herrmann S3, Berzins B4, Lecoeur S5, Diouf A6, Fournier-Nicolle I7, Lau J8, Schechter M9, Chassany O10

 

1Centre Hospitalier Universitaire de Bicetre, Le Kremlin-Bicetre, France, 2Hôpital Saint Louis, Paris, France, 3Royal Perth Hospital, Perth, Australia, 4Northwestern University, Chicago, Chicago, IL, USA, 5Programme for HIV Prevention and Treatment (PHPT), Chiang Mai, Thailand, 6Centre de Recherche Clinique de Fann (CRCFP), Dakar, Senegal, 7Hôpital Calmette, Phnom Penh, Cambodia, 8Chinese University of Hong Kong, Hong Kong, China, 9Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 10Assistance Publique - Hopitaux de Paris, Paris, France

16:30 - 17:30
WILLINGNESS TO PAY STUDIES

WP1

COMPARISON OF A DIRECT AND AN INDIRECT METHOD TO DERIVE WILLINGNESS TO PAY FOR COMPLEX HEALTH STATES IN OBSTETRICS

 

Bijlenga D1, Bonsel GJ2, Birnie E2

 

1Academic Medical Centre, Amsterdam, The Netherlands, 2Erasmus Medical Centre, Rotterdam, The Netherlands

WP2

VALUE OF POSTOPERATIVE ACUTE PAIN CARE FOR PATIENTS OPERATED BY LAPAROTOMY IN A DEPARTMENT OF DIGESTIVE SURGERY IN A FRENCH UNIVERSITY HOSPITAL: A WILLINGNESS TO PAY STUDY

 

Bocquet F1, Thiriat N1, Beaussier M1, Aissou M1, Preziosi C1, Borget I2, Tilleul P1

 

1St-Antoine Hospital, Paris, France, 2Institut de Cancérologie Gustave Roussy, Villejuif, France

WP3

ASSESSING THE WILLINGNESS-TO-PAY (WTP) FOR INTRADERMAL INFLUENZA VACCINATION IN AUSTRALIA USING DISCRETE CHOICE METHODOLOGY

 

Adams J1, Price N2, Mason G3

 

1IMS Health, St Leonards, NSW, Australia, 2Sanofi-Aventis, Sydney, NSW, Australia, 3Sanofi Pasteur, Sydney, NSW, Australia

PCV137

PREFERENCES OF PATIENTS, PHYSICIANS AND CAREGIVERS IN THE CHOICE OF ABDOMINAL AORTIC ANEURYSMS TREATMENT OPTIONS: THE PREFER STUDY

 

Scalone L1, Borghetti F2, Faggioli G3, Stella A3, Cortesi P2, Mantovani LG4

 

1University of Milan – Bicocca, Milan, Italy, 2University of Milan, Milan, Italy, 3Sant'Orsola Malpighi Hospital-University of Bologna, Bologna, Italy, 4University of Naples, Federico II, Naples, Italy
17:30 – 18:30
POSTER AUTHOR DISCUSSION HOUR – SESSION II
17:30 – 19:00
EXHIBITORS’ WINE & CHEESE RECEPTION
19:00 – 24:30
SOCIAL EVENT - Guided City Tour & Parisian Dinner
(Separate Registration Required - REGISTER NOW)
12th Annual European Congress Main Page

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2010 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.